Arcturus Therapeutics to Report Fourth Quarter and Fiscal Year 2025 Financial Results and Provide Corporate Update on March 3, 2026

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading company in messenger RNA (mRNA) medicines, is set to release its financial results for the fourth quarter and fiscal year ended December 31, 2025, on March 3, 2026, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time the same day, providing a platform for discussing these results along with a corporate update.

Founded in 2013 and headquartered in San Diego, California, Arcturus is renowned for its innovative mRNA technologies, which include the LUNAR® lipid-mediated delivery system and STARR® mRNA technology. The company made headlines with the rollout of KOSTAIVE®, the first approved self-amplifying mRNA COVID-19 vaccine. Arcturus has established various strategic collaborations, including a significant partnership with CSL Seqirus and the U.S. BARDA for pandemic flu initiatives, alongside a joint venture in Japan aimed at mRNA vaccine production.

Arcturus’ active pipeline showcases its commitment to addressing rare respiratory and liver diseases, with candidates targeting conditions such as cystic fibrosis and ornithine transcarbamylase deficiency. The company's versatile RNA therapeutic platforms extend beyond mRNA to include small interfering RNA (siRNA), circular RNA, antisense RNA, and DNA therapeutics, enhancing its capacity to develop innovative treatments.

With a robust patent portfolio encompassing over 500 patents globally, Arcturus is positioned to be at the forefront of mRNA technology advancements. This upcoming financial report offers an essential opportunity for stakeholders to gain insights into the company’s progress, strategic direction, and financial health as it continues to make strides in the dynamic biopharmaceutical landscape. For further details, visit www.ArcturusRx.com or connect with Arcturus on X and LinkedIn.

As Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) prepares to report its fourth quarter and fiscal year 2025 financial results on March 3, 2026, investors should anticipate potential volatility in the stock as the market reacts to both financial metrics and corporate updates. With its focus on messenger RNA (mRNA) medicines and vaccine development, particularly through its innovative technologies like LUNAR® and STARR®, the quarterly report could provide valuable insights into its ongoing projects and partnerships.

Expectations for Arcturus’s earnings may hinge on its revenue from current collaborations, notably with CSL Seqirus and BARDA, as well as any updates on its therapeutic pipeline for rare diseases like cystic fibrosis and OTC deficiency. Given that the company has already achieved significant milestones, including the world’s first authorized self-amplifying mRNA COVID vaccine, investors should be particularly attentive to any announcements regarding further advancements in its pipeline.

Analysts will likely scrutinize R&D expenses, as continued investment in product development is crucial for maintaining Arcturus’s competitive edge in a burgeoning field. Investors should also evaluate the company’s cash runway, as a robust financial position is critical for sustaining long-term projects, especially as the company transitions from development to commercialization phases.

In terms of stock performance, if Arcturus reports solid revenue growth and provides strategic insights suggesting a path toward profitability, it could prompt positive market reactions. Conversely, any disappointments such as lower-than-expected revenues or regulatory hurdles could lead to bearish sentiment.

Overall, monitoring the upcoming earnings call, where management will provide a corporate update and answer questions, will be vital for informed investment decisions. As always, thorough due diligence and consideration of market conditions should guide investment strategies in this dynamic sector.